220648-78-2

Basic information

• Product Name: TERT-BUTYL 4-(N-HYDROXYCARBAMIMIDOYL)-BENZYLCARBAMATE
• Synonyms: TERT-BUTYL 4-(N-HYDROXYCARBAMIMIDOYL)-BENZYLCARBAMATE;N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]Carbamic acid 1,1-dimethylethyl ester
• CAS NO: 220648-78-2
• Molecular Formula: C₁₃H₁₉N₃O₃
• Molecular Weight: 265.30826
• Mol File: 220648-78-2.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 363.1 °C at 760 mmHg
• Flash Point: 173.4 °C
• Appearance: /
• Density: 1.166 g/cm³
• Water Solubility: at 25 deg C (mg/L): 667.6
• CAS DataBase Reference: TERT-BUTYL 4-(N-HYDROXYCARBAMIMIDOYL)-BENZYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(N-HYDROXYCARBAMIMIDOYL)-BENZYLCARBAMATE(220648-78-2)
• EPA Substance Registry System: TERT-BUTYL 4-(N-HYDROXYCARBAMIMIDOYL)-BENZYLCARBAMATE(220648-78-2)

Safety Data

• Hazardous Substances Data: 220648-78-2(Hazardous Substances Data)

Upstream product

• 66389-80-8 tert-butyl N-[(4-cyanophenyl)methyl]carbamate 
• 15996-76-6 4-cyanobenzylamine hydrochloride 
• 10406-25-4 4-aminobenzyl cyanide 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1016261-59-8 {4-[5-(2-methyl-biphenyl-4-yl)-[1,2,4]oxadiazol-3-yl]-benzyl}-carbamic acid tert-butyl ester 
• 220648-80-6 tert-butyl 4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzylcarbamate 
• 1097196-63-8 3-[4-(aminomethyl)phenyl]-1,2,4-oxadiazol-5(4H)-one hydrochloride 
• 217313-79-6 4-(aminomethyl)benzene-1-carboximidamide dihydrochloride 
• 1433206-28-0 N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]carbamic acid tert-butyl ester 
• 1433205-40-3 4-(pyridin-3-yl)-N-(4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)pyrimidin-2-amine,trifluroacetic acid salt 
• 510771-81-0 (4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)phenyl)methanamine 
• 380237-42-3 Boc-4-acetylhydroxyamidinobenzylamide 
• 380237-44-5 C₁₇H₂₄N₄O₅ 
• 600707-97-9 C₁₀H₁₃N₃O₂ 
• 380237-42-3 C₁₅H₂₁N₃O₄ 

Relevant articles and documents

4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT

There are provided 4-alkynylimidazole derivatives represented by the following general formula (I) or phamaceutically acceptable salts thereof; the derivatives have a superior EP4 receptor antagonistic action and are useful as pharmaceuticals for the trea

Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor

PACE4 plays an important role in the progression of prostate cancer and is an attractive target for the development of novel inhibitor-based tumor therapies. We previously reported the design and synthesis of a novel, potent, and relatively selective PACE4 inhibitor known as a Multi-Leu (ML) peptide. In the present work, we examined the ML peptide through detailed structure-activity relationship studies. A variety of ML-peptide analogues modified at the P8-P5 positions with leucine isomers (Nle, DLeu, and DNle) or substituted at the P1 position with arginine mimetics were tested for their inhibitory activity, specificity, stability, and antiproliferative effect. By incorporating d isomers at the P8 position or a decarboxylated arginine mimetic, we obtained analogues with an improved stability profile and excellent antiproliferative properties. The DLeu or DNle residue also has improved specificity toward PACE4, whereas specificity was reduced for a peptide modified with the arginine mimetic, such as 4-amidinobenzylamide.

INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES

Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat